Skip to main content
. 2017 May 31;16:71. doi: 10.1186/s12933-017-0550-6

Fig. 2.

Fig. 2

Target of oral anti-aggregant drugs in platelets: thienopyridine (clopidogrel and prasugrel) and non-thienopyridine (ticagrelor and cangrelor) directly or indirectly inhibit ADP receptor P2Y12, thus limiting adenylate cyclase inhibition and platelet aggregation